Tomoko Arakaki
University of Buenos Aires
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomoko Arakaki.
European Journal of Neurology | 2015
Pablo Martinez-Martin; Kallol Ray Chaudhuri; Jose Manuel Rojo-Abuin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M. Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry Moore; Mayela Rodríguez-Violante; Carlos Singer; Barbara C. Tilley; Jing Huang; Glenn T. Stebbins; Christopher G. Goetz
Although Parkinsons disease (PD) is characterized by typical motor manifestations, non‐motor symptoms (NMS) are an outstanding part of the disease. At present, several specific instruments for assessment of NMS are available. The objective of our study was to determine the performance of the Movement Disorder Society‐Unified Parkinsons Disease Rating Scale (MDS‐UPDRS): Part I – Non‐Motor Aspects of Experiences of Daily Living (nM‐EDL) compared with the Non‐Motor Symptoms Scale (NMSS).
European Journal of Neurology | 2014
Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Maria João Forjaz; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M. Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry Moore; Mayela Rodríguez-Violante; Carlos Singer; Barbara C. Tilley; Jing Huang; Glenn T. Stebbins; Christopher G. Goetz
The Movement Disorder Society sponsored version of the Unified Parkinsons Disease Rating Scale (MDS‐UPDRS) is a comprehensive instrument for assessing Parkinsons disease (PD). The present study was aimed at determining the relationships between MDS‐UPDRS components and health‐related quality of life (HRQoL) evaluations in PD patients.
Movement Disorders | 2004
Nelida Garretto; José A. Bueri; R. Rey; Tomoko Arakaki; Gabriela Ñano; Marcela Mancuso
Zolpidem (ZLP) is an imidazopyridine that binds to GABA receptors. We report on improvement of blepharospasm in 3 patients treated with ZLP. The GABAergic action of this drug on the output structures of the basal ganglia could explain the improvement of blepharospasm in these patients.
Parkinsonism & Related Disorders | 2016
Leire Ambrosio; Mari Carmen Portillo; Carmen Rodriguez-Blazquez; Juan Carlos Martinez-Castrillo; Mayela Rodríguez-Violante; Marcos Serrano-Dueñas; Víctor Campos-Arillo; Nelida Garretto; Tomoko Arakaki; Mario Alvarez; Ivonne Pedroso-Ibáñez; Ana Carvajal; Pablo Martínez-Martín
INTRODUCTION To explore the psychometric attributes of a new Satisfaction with Life Scale (SLS-6) in a wide Spanish-speaking population with Parkinsons disease (PD). METHODS This was an international, cross-sectional study. Several rater-based and patient-reported outcomes measures for evaluation of PD (e.g., Scales for Outcomes in Parkinsons Disease-Motor) and other constructs (e.g., Duke-UNC Functional Social Support Questionnaire, Scale for Living with Chronic Illness) were applied together with the SLS-6. Acceptability, scaling assumptions, reliability, precision, and construct validity were tested. RESULTS The study included 324 patients from five countries, with age (mean ± standard deviation) 66.67 ± 10.68 years. None of the SLS-6 items had missing values and all acceptability parameters fulfilled the standard criteria. Scaling assumptions allowed the calculation of a summary index from items 2 to 6, complementary to the global evaluation (item 1). For these five items, Cronbachs alpha was 0.85; the corrected item-total correlation 0.53-0.73; inter-item correlation, 0.45-0.70, with an item homogeneity index of 0.55. The standard error of measurement, based on Cronbachs alpha for a single observation, was 3.48. SLS-6 correlations were moderate to strong (rs ≥ 0.35) with the patient-reported outcomes and weak to moderate with the rater-based assessments used in the study. The SLS-6 total score was significantly different according to PD severity levels established according to Hoehn and Yahr staging, Clinical Impression of Severity Index, and Patient-Based Global Impression of Severity scale. CONCLUSION The results suggest that SLS-6 is an easy, feasible, acceptable, consistent, precise and valid measure to evaluate satisfaction with life in PD patients.
Arquivos De Neuro-psiquiatria | 2013
Luz Abaroa; Sergio Alejandro Rodríguez-Quiroga; Luciana Melamud; Tomoko Arakaki; Nelida Garretto; Andres Villa
UNLABELLED Tonic spasms have been most commonly associated with multiple sclerosis. To date, few reports of series of patients with neuromyelitis optica and tonic spasms have been published. METHODS We analyzed the characteristics and frequency of tonic spasms in 19 subjects with neuromyelitis optica. Data was collected using a semi-structured questionnaire for tonic spasms, by both retrospectively reviewing medical records and performing clinical assessment. RESULTS All patients except one developed this symptom. The main triggering factors were sudden movements and emotional factors. Spasms were commonly associated to sensory disturbances and worsened during the acute phases of the disease. Carbamazepine was most commonly used to treat the symptom and patients showed good response to the drug. CONCLUSIONS Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica.
npj Parkinson's disease | 2016
Pablo Martinez-Martin; Jose Manuel Rojo-Abuin; Mayela Rodríguez-Violante; Marcos Serrano-Dueñas; Nelida Garretto; Juan Carlos Martínez-Castrillo; Víctor Campos Arillo; William Fernández; Pedro Chaná-Cuevas; Tomoko Arakaki; Mario Alvarez; Ivonne Pedroso Ibáñez; Carmen Rodriguez-Blazquez; Kallol Ray Chaudhuri; Marcelo Merello
Global evaluations of Parkinson’s disease (PD) severity are available, but their concordance and accuracy have not been previously tested. The present international, cross-sectional study was aimed at determining the agreement level among four global scales for PD (Hoehn and Yahr, HY; Clinical Global Impression of Severity, CGIS; Clinical Impression of Severity Index, CISI-PD; and Patient Global Impression of Severity, PGIS) and identifying which of them better correlates with itemized PD assessments. Assessments included additional scales for evaluation of the movement impairment, disability, affective disorders, and quality of life. Spearman correlation coefficients, weighted and generalized kappa, and Kendall’s concordance coefficient were used. Four hundred thirty three PD patients, 66% in HY stages 2 or 3, mean disease duration 8.8 years, were analyzed. Correlation between the global scales ranged from 0.60 (HY with PGIS) to 0.91 (CGIS with CISI-PD). Kendall’s coefficient of concordance resulted 0.76 (P<0.0001). HY and CISI-PD showed the highest association with age, disease duration, and levodopa-equivalent daily dose, and CISI-PD with measures of PD manifestations, disability, and quality of life. PGIS and CISI-PD correlated similarly with anxiety and depression scores. The lowest agreement in classifying patients as mild, moderate, or severe was observed between PGIS and HY or CISI-PD (58%) and the highest between CGIS and CISI-PD (84.3%). The four PD global severity scales agree moderately to strongly among them; clinician-based ratings estimate PD severity, as established by other measures, better than PGIS; and the CISI-PD showed the highest association with measures of impairment, disability, and quality of life.
Movement Disorders Clinical Practice | 2017
Matej Skorvanek; Pablo Martinez-Martin; Norbert Kovács; Mayela Rodríguez-Violante; Jean-Christophe Corvol; Pille Taba; Klaus Seppi; O. S. Levin; Anette Schrag; Thomas Foltynie; Mario Alvarez-Sanchez; Tomoko Arakaki; Zsuzsanna Aschermann; Iciar Aviles-Olmos; Eve Benchetrit; Charline Benoit; Alberto Bergareche-Yarza; Amin Cervantes-Arriaga; Anabel Chade; Florence Cormier; Veronika Datieva; David A. Gallagher; Nelida Garretto; Zuzana Gdovinova; Oscar Gershanik; Milan Grofik; Vladimir Han; Jing Huang; Liis Kadastik-Eerme; Monica M. Kurtis
The Movement Disorder Society Unified Parkinsons Disease Rating Scale (MDS‐UPDRS) is a newly developed tool to assess Parkinsons disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS‐UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD.
npj Parkinson's disease | 2016
Leire Ambrosio; Mari Carmen Portillo; Carmen Rodriguez-Blazquez; Mayela Rodríguez-Violante; Juan Carlos Martínez Castrillo; Víctor Campos Arillo; Nelida Garretto; Tomoko Arakaki; Marcos Serrano Dueñas; Mario Alvarez; Ivonne Pedroso Ibáñez; Ana Carvajal; Pablo Martinez-Martin
Understanding how a person lives with a chronic illness, such as Parkinson’s disease (PD), is necessary to provide individualized care and professionals role in person-centered care at clinical and community levels is paramount. The present study was aimed to analyze the psychometric properties of the Living with Chronic Illness-PD Scale (EC-PC) in a wide Spanish-speaking population with PD. International cross-sectional study with retest was carried out with 324 patients from four Latin American countries and Spain. Feasibility, acceptability, scaling assumptions, reliability, precision, and construct validity were tested. The study included 324 patients, with age (mean±s.d.) 66.67±10.68 years. None of the EC-PC items had missing values and all acceptability parameters fulfilled the standard criteria. Around two-third of the items (61.54%) met scaling assumptions standards. Concerning internal consistency, Cronbach’s alpha values were 0.68–0.88; item-total correlation was >0.30, except for two items; item homogeneity index was >0.30, and inter-item correlation values 0.14–0.76. Intraclass correlation coefficient for EC-PC stability was 0.76 and standard error of measurement (s.e.m.) for precision was 8.60 (for a EC-PC s.d.=18.57). EC-PC presented strong correlation with social support (rS=0.61) and moderate correlation with life satisfaction (rS=0.46). Weak and negligible correlations were found with the other scales. Internal validity correlations ranged from 0.46 to 0.78. EC-PC total scores were significantly different for each severity level based on Hoehn and Yahr and Clinical Impression of Severity Index, but not for Patient Global Impression of Severity. The EC-PC has satisfactory acceptability, reliability, precision, and validity to evaluate living with PD.
Arquivos De Neuro-psiquiatria | 2006
Carlos G. Abel; Gustavo Stein; Silvia Pereyra; Gabriela Ñano; Tomoko Arakaki; Nelida Garretto; Carlos Mangone; Osvaldo Genovese; Roberto E.P. Sica
OBJECTIVE To compare executive functions (EF) in non-demented mild to moderate Parkinsons disease (PD) (Hoehn and Yahr < or =3) and pure degenerative cerebellar disease (CD) in order to evaluate the relative contribution and differential role of basal ganglia and cerebellum in those functions. METHOD 14 patients with PD and 14 patients with CD matched by sex, education, diseases duration and MMSE were selected. A standardized neuropsychological battery and the Wisconsin Card Sorting Test (WCST) were administered. Z scores were compared for both groups through t-test for independent samples were used. RESULTS The cerebellar group showed significant lower performance in measures of attention and EF, with a significant increase in both perseverative and non perseverative errors during the WCST. On the other hand the PD group showed a selective increase of non perseverative errors, without reaching significant between group difference. CONCLUSION The CD group appears to have greater deficits in EF with a pattern of prefrontal dysfunction.
Parkinsonism & Related Disorders | 2018
Matej Skorvanek; Pablo Martinez-Martin; Norbert Kovács; Ivan Zezula; Mayela Rodríguez-Violante; Jean-Christophe Corvol; Pille Taba; Klaus Seppi; O. S. Levin; Anette Schrag; Iciar Aviles-Olmos; Mario Alvarez-Sanchez; Tomoko Arakaki; Zsuzsanna Aschermann; Eve Benchetrit; Charline Benoit; Alberto Bergareche-Yarza; Amin Cervantes-Arriaga; Anabel Chade; Florence Cormier; Veronika Datieva; David A. Gallagher; Nelida Garretto; Zuzana Gdovinova; Oscar Gershanik; Milan Grofik; Vladimir Han; Liis Kadastik-Eerme; Monica M. Kurtis; Graziella Mangone
BACKGROUND The relationship between Health-Related Quality of Life (HRQoL) and MDS-UPDRS has not been fully studied so far. The aim of this study was to evaluate the relationship between all MDS-UPDRS components and HRQoL in a representative international cohort of PD patients. METHODS We collected demographic and disease-related data as well as MDS-UPDRS and PDQ8 scales. Data were analyzed using correlations between PDQ8 and all MDS-UPDRS items, subsequently two hierarchical multiple regressions were performed, first between the scores of the MDS-UPDRS Parts and PDQ8 and second between individual items from those Parts demonstrating significant relationship to PDQ8 scores in the first regression. LASSO regression analyses were performed to evaluate the relationship between PDQ8 and all individual MDS-UPDRS items. RESULTS A total of 3206 PD patients were included in the study. In the first regression analysis, PDQ8 was significantly related to MDS-UPDRS parts I and II, but not to III and IV. In the second regression model, significant contributions to PDQ8 were found for Part I items Fatigue, Pain, Depressed mood, Apathy; and Part II items Dressing, Doing hobbies, Freezing, Speech and Tremor. In the LASSO analysis, six Part I, seven Part II, three Part III and one Part IV items contributed to PDQ8 scores. The five items most significantly related to the model were Depressed mood, Dressing, Apathy, Pain and Fatigue. CONCLUSIONS This is so far the largest study related to HRQoL issues in PD. Restrictions in activities of daily living and non-motor symptoms significantly contribute to HRQoL in PD.